Document Type : Original Article(s)
Authors
- Mohamed Khalifa 1
- Amrallah Mohammed 1
- Yara Mohamed 1
- Isra Mahgoub 1
- Mohamed Awadallah 1
- Basant SH. Elshafaay 2
- Amira Hanna 2
- Ahmed Obaya 2
- Yaser Arafat 1
1 Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt
2 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Egypt
Abstract
Background: This study aimed to assess the effect of proton pump inhibitors (PPIs) on hormone receptor-positive (HR+) and her-2-negative (her2-) metastatic breast cancer (MBC) in patients receiving CDK4/6i.
Method: In a retrospective study, patients were divided into two groups based on their use of PPIs: concomitant use for at least half the treatment period (C-PPIs) and non-concomitant use for less than half the treatment period (NC-PPIs). Statistical analyses were conducted using SPSS 22.0 and MedCalc Software bvba 13.
Results: Out of 217 patients, 114 (52.5%) received palbociclib and 103 (47.5%) received ribociclib. Then, 71 palbociclib recipients were combined with aromatase inhibitors (AIs) (43 C-PPIs and 28 NC-PPIs), while 43 were combined with fulvastrant (25 C-PPIs and 18 NC-PPIs). For ribociclib, 82 patients were combined with AIs (71 C-PPIs and 11 NC-PPIs) and 21 were combined with fulvastrant (10 C-PPIs and 11 NC-PPIs). Patients with C-PPI had lower progression-free survival (PFS) than those without C-PPI, palbociclib recipients with AIs or fulvastrant (8.97 months vs. 19.02 months, P < 0.001; 13.72 months vs. 18.52 months, P = 0.04, respectively) and ribociclib recipients with AIs (10.7 months vs. 19.7 months, P = 0.05), but not in patients who received ribociclib with fulvastrant (P = 0.52).
Conclusion: The simultaneous use of PPIs with palbociclib or ribociclib may be associated with a shorter PFS in HR+, HER2- MBC patients. These results have the potential to enhance clinical decision-making by identifying possible drug interactions and optimizing treatment plans.
Highlights
Amrallah Mohammed (PubMed)
Keywords
Main Subjects
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.30476/mejc.2024.102264.2080
- Elfgen C, Montagna G, Schmid SM, Bierbauer W, Güth U. Metastatic breast cancer as a chronic disease: Evidence-based data on a theoretical concept. Breast Care (Basel). 2020;15(3):281-8. doi: 10.1159/000502636. PMID: 32774223; PMCID: PMC7383269.
- Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi: 10.1093/jnci/dju055. PMID: 24777111; PMCID: PMC4580552.
- Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017;59:22-32. doi: 10.1016/j.ctrv.2017.06.004. PMID: 28719836.
- Matutino A, Joy AA, Brezden-Masley C, Chia S, Verma S. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Curr Oncol. 2018;25(Suppl 1):S131-S141. doi: 10.3747/co.25.4000. PMID: 29910656; PMCID: PMC6001771.
- Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: A systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6400. doi: 10.3390/ijms21176400. PMID: 32899139; PMCID: PMC7503849.
- Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, et al Prevalence of acid‐reducing agents (ARA) in cancer populations and ARA drug‐drug interaction potential for molecular targeted agents in clinical development. Mol Pharm.2013;10(11):4055-62. doi: 10.1021/mp400403s. PMID: 24044612.
- Numico G, Fusco V, Franco P, Roila F. Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use. Crit Rev Oncol Hematol.2017;111:144-51. doi: 10.1016/j.critrevonc.2017.01.014. PMID: 28259289.
- Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-84. doi: 10.1200/JCO.2017.73.7585. PMID: 28580882.
- Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. PMID: 34509802; PMCID: PMC8441157.
- Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4thESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) dagger. Ann Oncol.2018;29(8):1634-57. doi: 10.1093/annonc/mdy192. PMID: 30032243; PMCID: PMC7360146.
- de Moraes FCA, Pereira CRM, Sano VKT, Laia EA, Stecca C, Burbano RMR. Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis. Front Pharmacol. 2024;15:1352224. doi: 10.3389/fphar.2024.1352224. PMID: 38769999; PMCID: PMC11102992.
- Çağlayan D, Koçak MZ, Geredeli Ç, Tatlı AM, Göksu SS, Eryılmaz MK, et al. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. Eur J Clin Pharmacol.2023;79(2):243-8. doi: 10.1007/s00228-022-03435-7. PMID: 36520173.
- Eser K, Önder AH, Sezer E, Çil T, İnal A, Öztürk B, et al. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer.2022;22(1):516. doi: 10.1186/s12885-022-09624-y. PMID: 35525929; PMCID: PMC9078089.
- Goldstein MJ, Peters M, Weber BL, Davis CB. Optimizing the therapeutic window of targeted drugs in oncology: potency-guided first-in-human studies. Clin Transl Sci.2021;14(2):536-43. doi: 10.1111/cts.12902. PMID: 33048459; PMCID: PMC7993318.
- Schieber T, Steele S, Collins S, Berger M, Fleming M, McLaughlin E, et al. Effect of concurrent proton pump inhibitors with palbociclib tablets for metastatic breast cancer. Clin Breast Cancer. 2023;23(6):658-63. doi: 10.1016/j.clbc.2023.05.009. PMID: 37296062.
- Lee JE, Kwon SH, Kwon S, Jung HI, Nam JH, Lee EK. Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer. JAMA Netw Open. 2023;6(7):e2324852. doi: 10.1001/jamanetworkopen.2023.24852. PMID: 37477917; PMCID: PMC10362477.
- Samant TS, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A, et al. Ribociclib bioavailability is not affected by gastric pH changes or food intake: In silico and clinical evaluations. 2018;104(2):374-83. doi: 10.1002/cpt.940. PMID: 29134635; PMCID: PMC6099197.
- Lu Y, Yang S, Ho YY, Ji Y. Ribociclib population pharmacokinetics and pharmacokinetic/pharmacodynamic analysis of neutrophils in cancer patients. J Clin Pharmacol.2021;61(8):1054-68. doi: 10.1002/jcph.1856. PMID: 33713359.
- Odabas H, Dogan A, Ozcelik M, Yildirim S, Ozkerim U, Turan N, et al. Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer? Medicina (Kaunas). 2023;59(3):557. doi: 10.3390/medicina59030557. PMID: 36984558; PMCID: PMC10052377.
- Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Efect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21(6):962-76. doi: 10.1016/j.drudis.2016.03.002. PMID: 26995271.
- Ihraiz WG, Ahram M, Bardaweel SK. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharm.2020;70(2):179-90. doi: 10.2478/acph-2020-0020. PMID: 31955147.
- Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line geftinib treatment-a nation - wide population-based study. Cancer Manag Res.2019;11:8539-46. doi: 10.2147/CMAR.S222278. PMID: 31572008; PMCID: PMC6756852.
- Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression afectsunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract.2015;21(3):194-200. doi: 10.1177/1078155214527145. PMID: 24664477.
- Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15(6):724-32. doi: 10.1016/j.clgc.2017.05.019. PMID: 28645482.
- McAlister RK, Aston J, Pollack M, Du L, Koyama T, Chism D. Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. 2018;23(6):686-92. doi: 10.1634/theoncologist.2017-0578. PMID: 29487220; PMCID: PMC6067930.
- Veerman GDM, Hussaarts KGAM, Peric R, Oomen-de Hoop E, Landa KD, van der Leest CH, et al. Influence of cow's milk and esomeprazole on the absorption of Erlotinib: A randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. doi: 10.1007/s40262-020-00910-1. PMID: 32557346; PMCID: PMC7808986.
- Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, et al. Impact of Use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: A systematic review and meta-analysis. Cancers (Basel).2020;12(4):998. doi: 10.3390/cancers12040998. PMID: 32325628; PMCID: PMC7226385.
)